Please login to the form below

Not currently logged in

Roche to buy Anadys for $230m

Roche is to acquire US-based Anadys Pharmaceuticals for $230m, developing the company's hepatitis C capabilities

Roche is to acquire US-based Anadys Pharmaceuticals for $3.70 per share – about $230m in total.

Anadys specialises in the development of oral, small molecule therapeutics for the potential treatment of hepatitis C virus infection.

The deal will see Roche take ownership of the drug candidate setrobuvir (ANA598), which is currently in a phase II study in combination with Roche's (Pegasys) pegylated interferon and (Copegus) ribavirin.

Other products in development include ANA773, which is currently at phase I trial stage for the treatment of hepatitis C as well as other chronic infections and cancer.

Jean-Jacques Garaud, global head of Roche pharmaceutical research and early development, said the acquisition would enhance the company's presence in the treatment of hepatitis C.

He said: "Our aim is to offer physicians and hepatitis patients a powerful combination of therapies that bring us closer to a cure, even without the use of interferon."

17th October 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....